State and territorial health departments have the ability to order COVID-19 therapeutic products seven days a week through the Health Partner Ordering Portal (HPOP) in a process known as “threshold and replenishment.” In this process, the federal government replenishes the available supply, replacing products ordered by sites in the jurisdiction the previous week. This ensures that the total amount of product available to jurisdictions each week is consistent, and this amount is known as a jurisdiction’s "threshold quantity."
Paxlovid and Lagevrio (molnupiravir) threshold amounts are determined on a pro rata population basis and replenishment occurs weekly.
Requests for additional products can be made by state and territorial health department officials at any time if the current supply is not sufficient to meet demand. The federal government tracks the amount of COVID-19 therapeutic products ordered through the HPOP portal each week, monitoring product availability for each state or territory.
COVID-19 Therapeutics Summary: For All Open Distribution Channels1
December 17, 2021 – March 19, 2023
| Therapeutic |
Courses Delivered |
Courses Administered2 |
| Paxlovid3 |
12,776,335 |
8,640,385 |
| Lagevrio |
2,949,282 |
1,249,083 |
Total:
View Data by Jurisdiction |
15,725,617 |
9,889,468 |
1States, territories, and federal entities, including HRSA
2Based on 92% of sites reporting as of March 19, 2023
3Includes Paxlovid and Renal Paxlovid
Data source: HHS-Tiberius
COVID-19 Therapeutics Summary: Previously Distributed Products
2020 – 2023
Therapeutics
(currently not in use) |
Courses Delivered |
Courses Administered |
| Evusheld (300mg doses) |
1,032,156 |
738,936 |
| Bebtelovimab |
739,889 |
624,633 |
| REGEN-COV |
2,878,138 |
2,078,587 |
| Bamlanivimab/Etesevimab |
642,125 |
610,753 |
| Sotrovimab |
706,692 |
302,209 |
COVID-19 Therapeutics Threshold Determinations
September 5, 2022 – March 26, 2023
|
|
Paxlovid
(Standard and Renal) |
Lagevrio
(molnupiravir) |
Evusheld |
Total |
|
March 20 - March 26, 2023 |
612,165 |
48,604 |
- |
660,769 |
|
March 13 - March 19, 2023 |
612,165 |
48,604 |
- |
660,769 |
|
March 6 - March 12, 2023 |
612,165 |
48,604 |
- |
660,769 |
|
February 27 - March 5, 2023 |
613,705 |
49,099 |
- |
662,804 |
|
February 20 - February 26, 2023 |
612,165 |
48,604 |
- |
660,769 |
|
February 13 - February 19, 2023 |
612,165 |
48,604 |
- |
660,769 |
|
February 6 - February 12, 2023 |
612,115 |
48,296 |
- |
660,411 |
|
January 30 - February 5, 2023 |
613,655 |
48,791 |
- |
662,446 |
|
January 23 - January 29, 2023 |
612,115 |
48,296 |
0 |
660,411 |
|
January 16 - January 22, 2023 |
612,115 |
48,296 |
0 |
660,411 |
|
January 9 - January 15, 2023 |
612,060 |
48,240 |
0 |
660,300 |
|
January 2 - January 8, 2023 |
613,580 |
48,735 |
204,096 |
866,411 |
|
December 26, 2022 - January 1, 2023 |
612,060 |
48,240 |
0 |
660,300 |
|
December 19 - December 25, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
December 12 - December 18, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
December 5 - December 11, 2022 |
613,580 |
48,735 |
204,096 |
866,411 |
|
November 28 - December 4, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
November 21 - November 27, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
November 14 - November 20, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
November 7 - November 13, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
October 31 - November 6, 2022 |
613,580 |
48,735 |
204,096 |
866,411 |
|
October 24 - October 30, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
October 17 - October 23, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
October 10 - October 16, 2022 |
612,060 |
48,240 |
0 |
660,300 |
|
October 3 - October 9, 2022 |
613,580 |
48,735 |
204,096 |
866,411 |
|
September 26 - October 2, 2022 |
612,060 |
48,312 |
0 |
660,372 |
|
September 19 - September 25, 2022 |
612,060 |
91,920 |
0 |
703,980 |
|
September 12 - September 18, 2022 |
612,060 |
91,920 |
0 |
703,980 |
|
September 5 - September 11, 2022 |
612,060 |
91,920 |
0 |
703,980 |
Prior Distribution Efforts
